美国 · SEC FORM 4
Monte Rosa Therapeutics, Inc.
GLUE · Nasdaq · CIK 0001826457 · Healthcare · Biotechnology
内部人信号
当前没有活跃买入信号
0 qualifying P purchase groups
当前 180 天评分窗口
38 同一窗口内观察到的 Form 4 交易行
21 sales · 17 期权、代扣税、授予、赠与或其他交易行
最近一次合资格买入2025-03-24 · Leo Chandra P. · $58.4K
为什么没有活跃信号？
买入活动无
近期买入无
近期卖出High
买入信号状态未激活
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
AprMayJunJulAugSepOct
Champoux JenniferChief Operating Officer
○▼○▼○▼○▼○▼
Janku FilipChief Medical Officer
○▼○▼○▼○▼
Townson SharonChief Scientific Officer
○▼○▼○▼○▼
Manning Anthony M.Director
○▼○▼
Warmuth MarkusPresident & CEO
▼▼▼
Behbahani AliDirector
○
● 买入▼ 卖出○ 其他
Showing the six most active owners; 1 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
暂无已记录的活跃信号快照
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-03-24 · Leo Chandra P..
近期 Form 4 活动
0买入
37卖出
25其他 Form 4 交易行
33SEC 申报 · 365天
买入0 qualifying P line(s) · 180 days
卖出21 sale line(s) · 仅供背景
其他17 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 19,686,241
- 上期报告
- 19,265,990
- 日均成交量
- 1,093,381
- 回补天数
- 18.0
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-03-24 | Leo Chandra P. | 买入 (P) | Common Stock | 10,000 | USD 5.84 | USD 58,400 | SEC 申报 ↗ |
| 2021-06-28 | Yang Rick | 买入 (P) | Common Stock | 1,050,000 | USD 19.00 | USD 19,950,000 | SEC 申报 ↗ |
| 2021-06-28 | Walker Paul Edward | 买入 (P) | Common Stock | 1,050,000 | USD 19.00 | USD 19,950,000 | SEC 申报 ↗ |
| 2021-06-28 | Versant Vantage I GP, L.P.; Versant Vantage I GP-GP, LLC; Versant Vantage I, L.P.; Versant Venture Capital VI, L.P.; Versant Ventures VI GP, L.P.; Versant Ventures VI GP-GP, LLC | 买入 (P) | Common Stock | 157,895 | USD 19.00 | USD 3,000,005 | SEC 申报 ↗ |
| 2021-06-28 | Sonsini Peter W. | 买入 (P) | Common Stock | 1,050,000 | USD 19.00 | USD 19,950,000 | SEC 申报 ↗ |
| 2021-06-28 | SANDELL SCOTT D | 买入 (P) | Common Stock | 1,050,000 | USD 19.00 | USD 19,950,000 | SEC 申报 ↗ |
| 2021-06-28 | NEA 17 GP, LLC; NEA Partners 17, L.P.; New Enterprise Associates 17, L.P. | 买入 (P) | Common Stock | 1,050,000 | USD 19.00 | USD 19,950,000 | SEC 申报 ↗ |
| 2021-06-28 | Mathers Edward T | 买入 (P) | Common Stock | 1,050,000 | USD 19.00 | USD 19,950,000 | SEC 申报 ↗ |
| 2021-06-28 | Makhzoumi Mohamad | 买入 (P) | Common Stock | 1,050,000 | USD 19.00 | USD 19,950,000 | SEC 申报 ↗ |
| 2021-06-28 | MAKOWER JOSHUA | 买入 (P) | Common Stock | 1,050,000 | USD 19.00 | USD 19,950,000 | SEC 申报 ↗ |
| 2021-06-28 | Landsman Liza | 买入 (P) | Common Stock | 1,050,000 | USD 19.00 | USD 19,950,000 | SEC 申报 ↗ |
| 2021-06-28 | Florence Anthony A. Jr. | 买入 (P) | Common Stock | 1,050,000 | USD 19.00 | USD 19,950,000 | SEC 申报 ↗ |
| 2021-06-28 | Chen Bihua; Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Cormorant Private Healthcare Fund II, LP; Cormorant Private Healthcare Fund III LP | 买入 (P) | Common Stock | 600,000 | USD 19.00 | USD 11,400,000 | SEC 申报 ↗ |
| 2021-06-28 | Chang Carmen | 买入 (P) | Common Stock | 1,050,000 | USD 19.00 | USD 19,950,000 | SEC 申报 ↗ |
| 2021-06-28 | Bolzon Bradley J PhD | 买入 (P) | Common Stock | 157,895 | USD 19.00 | USD 3,000,005 | SEC 申报 ↗ |
Form 4 申报证据
62 transaction lines in the latest 365-day window; 145 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-05 | Bowen Matthew | 卖出 (S) | Common Stock | 13 | USD 10.56 | USD 137 | SEC 申报 ↗ |
| 2026-07-16 | Warmuth Markus | 卖出 (S) | Common Stock | 9,500 | USD 23.18 | USD 220,210 | SEC 申报 ↗ |
| 2026-07-15 | Champoux Jennifer | 卖出 (S) | Common Stock | 4,351 | USD 23.38 | USD 101,726 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-05 | Bowen Matthew | 卖出 (S) | Common Stock | 13 | USD 10.56 | USD 137 | SEC 申报 ↗ |
| 2026-07-16 | Warmuth Markus | 卖出 (S) | Common Stock | 9,500 | USD 23.18 | USD 220,210 | SEC 申报 ↗ |
| 2026-07-15 | Champoux Jennifer | 卖出 (S) | Common Stock | 4,351 | USD 23.38 | USD 101,726 | SEC 申报 ↗ |
| 2026-07-15 | Champoux Jennifer | 期权行权／转换 (M) | Common Stock | 4,351 | USD 3.98 | USD 17,317 | SEC 申报 ↗ |
| 2026-07-06 | Townson Sharon | 卖出 (S) | Common Stock | 6,000 | USD 23.31 | USD 139,852 | SEC 申报 ↗ |
| 2026-07-06 | Townson Sharon | 期权行权／转换 (M) | Common Stock | 6,000 | USD 6.14 | USD 36,840 | SEC 申报 ↗ |
| 2026-07-01 | Behbahani Ali | J (J) | Common Stock | 1,015,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-30 | Janku Filip | 卖出 (S) | Common Stock | 5,407 | USD 24.50 | USD 132,472 | SEC 申报 ↗ |
| 2026-06-30 | Janku Filip | 期权行权／转换 (M) | Common Stock | 5,407 | USD 13.41 | USD 72,508 | SEC 申报 ↗ |
| 2026-06-29 | Manning Anthony M. | 卖出 (S) | Common Stock | 10,000 | USD 23.11 | USD 231,100 | SEC 申报 ↗ |
| 2026-06-29 | Manning Anthony M. | 期权行权／转换 (M) | Common Stock | 10,000 | USD 4.16 | USD 41,600 | SEC 申报 ↗ |
| 2026-06-29 | Janku Filip | 卖出 (S) | Common Stock | 6,000 | USD 22.95 | USD 137,700 | SEC 申报 ↗ |
| 2026-06-29 | Janku Filip | 期权行权／转换 (M) | Common Stock | 6,000 | USD 7.56 | USD 45,360 | SEC 申报 ↗ |
| 2026-06-24 | Janku Filip | 卖出 (S) | Common Stock | 30,000 | USD 21.42 | USD 642,600 | SEC 申报 ↗ |
| 2026-06-24 | Janku Filip | 期权行权／转换 (M) | Common Stock | 30,000 | USD 7.56 | USD 226,800 | SEC 申报 ↗ |
| 2026-06-23 | Townson Sharon | 卖出 (S) | Common Stock | 3,000 | USD 20.00 | USD 60,000 | SEC 申报 ↗ |
| 2026-06-23 | Townson Sharon | 期权行权／转换 (M) | Common Stock | 3,000 | USD 6.14 | USD 18,420 | SEC 申报 ↗ |
| 2026-06-23 | Janku Filip | 卖出 (S) | Common Stock | 11,845 | USD 20.22 | USD 239,506 | SEC 申报 ↗ |
| 2026-06-23 | Janku Filip | 期权行权／转换 (M) | Common Stock | 6,000 | USD 7.56 | USD 45,360 | SEC 申报 ↗ |
| 2026-06-23 | Champoux Jennifer | 卖出 (S) | Common Stock | 2,175 | USD 20.00 | USD 43,500 | SEC 申报 ↗ |
| 2026-06-23 | Champoux Jennifer | 期权行权／转换 (M) | Common Stock | 2,175 | USD 3.98 | USD 8,656 | SEC 申报 ↗ |
| 2026-06-17 | Townson Sharon | 卖出 (S) | Common Stock | 3,000 | USD 19.00 | USD 57,000 | SEC 申报 ↗ |
| 2026-06-17 | Townson Sharon | 期权行权／转换 (M) | Common Stock | 3,000 | USD 6.14 | USD 18,420 | SEC 申报 ↗ |
| 2026-06-17 | Champoux Jennifer | 卖出 (S) | Common Stock | 2,176 | USD 19.00 | USD 41,344 | SEC 申报 ↗ |
| 2026-06-17 | Champoux Jennifer | 期权行权／转换 (M) | Common Stock | 2,176 | USD 3.98 | USD 8,660 | SEC 申报 ↗ |
| 2026-06-01 | Warmuth Markus | 卖出 (S) | Common Stock | 5,466 | USD 19.44 | USD 106,245 | SEC 申报 ↗ |
| 2026-05-29 | Townson Sharon | 卖出 (S) | Common Stock | 6,000 | USD 19.87 | USD 119,220 | SEC 申报 ↗ |
| 2026-05-29 | Townson Sharon | 期权行权／转换 (M) | Common Stock | 6,000 | USD 6.14 | USD 36,840 | SEC 申报 ↗ |
| 2026-05-27 | Champoux Jennifer | 卖出 (S) | Common Stock | 2,175 | USD 20.00 | USD 43,500 | SEC 申报 ↗ |
| 2026-05-27 | Champoux Jennifer | 期权行权／转换 (M) | Common Stock | 2,175 | USD 3.98 | USD 8,656 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | GLUE |
| CIK | 0001826457 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 145 transaction lines from 2021-06-28 to 2026-10-05 17 P purchase lines · 47 S sale lines · 81 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.